ProShares Ultra Bloomberg Natural Gas

Direxion Daily FTSE China Bull 3X ETF

United States Natural Gas

Direxion Daily Semicondct Bear 3X ETF

Direxion Daily TSLA Bull 1.5X Shares

ARK Genomic Revolution Multi-Sector ETF

ProShares Ultra Silver

Direxion Daily 20+ Yr Trsy Bear 3X ETF

Direxion Technology Bear 3X Shares

Global X Uranium ETF

ProShares UltraShort Bloomberg Natrl Gas

Exchange Traded Concepts Trust Range Global Coal Index ETF

Direxion Daily Semicondct Bull 3X ETF

iShares Ethereum Trust ETF

ProShares UltraShort Silver

Direxion Daily 20+ Yr Trsy Bull 3X ETF

Direxion Daily Technology Bull 3X ETF

iPath S&P 500 VIX ST Futures ETN

ProShares Ultra Semiconductors

iShares MSCI India

Siyata Mobile Inc. Common Shares

Eyenovia Inc. Common Stock

Edible Garden AG Incorporated Common Stock

MicroAlgo Inc. Ordinary Shares

D-Wave Quantum Inc. Common Shares

Pegasystems Inc. Common Stock

Pony AI Inc. American Depositary Shares

Green Plains Inc. Common Stock

RE/MAX Holdings Inc. Class A Common Stock

Bilibili Inc. American Depositary Shares

Protagenic Therapeutics Inc. Common Stock

Brainstorm Cell Therapeutics Inc. Common Stock

Incannex Healthcare Limited American Depositary Shares

ASP Isotopes Inc. Common Stock

Dycom Industries Inc. Common Stock

PetMed Express Inc. Common Stock

Ingersoll Rand Inc. Common Stock

iCoreConnect Inc. Common stock

Eagle Materials Inc Common Stock

Trip.com Group Limited American Depositary Shares

Click here to get full coverage on Theravance Biopharma Inc (TBPH) Q1 2025 Earnings Call Highlights: Strong Sales Growth and ... - Yahoo Finance

Theravance Biopharma Inc (TBPH) Q1 2025 Earnings Call Highlights: Strong Sales Growth and ...  Yahoo Finance

Theravance Biopharma Inc (TBPH) Q1 2025 Earnings Call Highlights: Strong Sales Growth and ... - Yahoo Finance

Click here to get full coverage on Theravance Biopharma to Participate in an Upcoming Investor Conference - Stock Titan

Theravance Biopharma to Participate in an Upcoming Investor Conference  Stock Titan

Theravance Biopharma to Participate in an Upcoming Investor Conference - Stock Titan

Click here to get full coverage on Theravance Biopharma, Inc. Reports Record Fourth Quarter and Full Year 2024 Financial Results - PR Newswire

Theravance Biopharma, Inc. Reports Record Fourth Quarter and Full Year 2024 Financial Results  PR Newswire

Theravance Biopharma, Inc. Reports Record Fourth Quarter and Full Year 2024 Financial Results - PR Newswire

Click here to get full coverage on Theravance Biopharma (TBPH) Reports Q1 Loss, Misses Revenue Estimates - MSN

Theravance Biopharma (TBPH) Reports Q1 Loss, Misses Revenue Estimates  MSN

Theravance Biopharma (TBPH) Reports Q1 Loss, Misses Revenue Estimates - MSN

Click here to get full coverage on We Think Some Shareholders May Hesitate To Increase Theravance Biopharma, Inc.'s (NASDAQ:TBPH) CEO Compensation - simplywall.st

We Think Some Shareholders May Hesitate To Increase Theravance Biopharma, Inc.'s (NASDAQ:TBPH) CEO Compensation  simplywall.st

We Think Some Shareholders May Hesitate To Increase Theravance Biopharma, Inc.'s (NASDAQ:TBPH) CEO Compensation - simplywall.st

Click here to get full coverage on New Phase 3 Analysis Reveals Ampreloxetine Impact on MSA Patients with Orthostatic Hypotension - Stock Titan

New Phase 3 Analysis Reveals Ampreloxetine Impact on MSA Patients with Orthostatic Hypotension  Stock Titan

New Phase 3 Analysis Reveals Ampreloxetine Impact on MSA Patients with Orthostatic Hypotension - Stock Titan

Click here to get full coverage on Theravance Announces Publication of YUPELRI® (revefenacin) Area Under the Curve Spirometry Analysis in the International Journal of Chronic Obstructive Pulmonary Disease - PR Newswire

Theravance Announces Publication of YUPELRI® (revefenacin) Area Under the Curve Spirometry Analysis in the International Journal of Chronic Obstructive Pulmonary Disease  PR Newswire

Theravance Announces Publication of YUPELRI® (revefenacin) Area Under the Curve Spirometry Analysis in the International Journal of Chronic Obstructive Pulmonary Disease - PR Newswire

Click here to get full coverage on Theravance Biopharma Inc (TBPH) Q1 2025 Earnings Report Preview: What To Expect - GuruFocus

Theravance Biopharma Inc (TBPH) Q1 2025 Earnings Report Preview: What To Expect  GuruFocus

Theravance Biopharma Inc (TBPH) Q1 2025 Earnings Report Preview: What To Expect - GuruFocus

Click here to get full coverage on Theravance Biopharma First Quarter 2025 Earnings: Misses Expectations - simplywall.st

Theravance Biopharma First Quarter 2025 Earnings: Misses Expectations  simplywall.st

Theravance Biopharma First Quarter 2025 Earnings: Misses Expectations - simplywall.st

Click here to get full coverage on Theravance Biopharma Inc (TBPH) Q4 2024 Earnings Call Highlights: Record Sales and Strategic ... - Yahoo Finance

Theravance Biopharma Inc (TBPH) Q4 2024 Earnings Call Highlights: Record Sales and Strategic ...  Yahoo Finance

Theravance Biopharma Inc (TBPH) Q4 2024 Earnings Call Highlights: Record Sales and Strategic ... - Yahoo Finance

Click here to get full coverage on Theravance Biopharma Announces Ampreloxetine Presentations at the International MSA Congress - Stock Titan

Theravance Biopharma Announces Ampreloxetine Presentations at the International MSA Congress  Stock Titan

Theravance Biopharma Announces Ampreloxetine Presentations at the International MSA Congress - Stock Titan

Click here to get full coverage on Theravance Biopharma (TBPH) Reports Q1 Revenue and Strategic Pro - GuruFocus

Theravance Biopharma (TBPH) Reports Q1 Revenue and Strategic Pro  GuruFocus

Theravance Biopharma (TBPH) Reports Q1 Revenue and Strategic Pro - GuruFocus

Click here to get full coverage on Theravance Biopharma Sets Q1 2025 Earnings Date: Key Financial Results Coming May 8 - Stock Titan

Theravance Biopharma Sets Q1 2025 Earnings Date: Key Financial Results Coming May 8  Stock Titan

Theravance Biopharma Sets Q1 2025 Earnings Date: Key Financial Results Coming May 8 - Stock Titan

Click here to get full coverage on Theravance Bio (TBPH) Soars 8.3%: Is Further Upside Left in the Stock? - Yahoo Finance

Theravance Bio (TBPH) Soars 8.3%: Is Further Upside Left in the Stock?  Yahoo Finance

Theravance Bio (TBPH) Soars 8.3%: Is Further Upside Left in the Stock? - Yahoo Finance

Click here to get full coverage on Theravance Biopharma, Inc. Reports First Quarter 2025 Financial Results and Provides Corporate Update - Stock Titan

Theravance Biopharma, Inc. Reports First Quarter 2025 Financial Results and Provides Corporate Update  Stock Titan

Theravance Biopharma, Inc. Reports First Quarter 2025 Financial Results and Provides Corporate Update - Stock Titan

Click here to get full coverage on Theravance Biopharma, Inc. (NASDAQ:TBPH) Q1 2025 Earnings Call Transcript - Insider Monkey

Theravance Biopharma, Inc. (NASDAQ:TBPH) Q1 2025 Earnings Call Transcript  Insider Monkey

Theravance Biopharma, Inc. (NASDAQ:TBPH) Q1 2025 Earnings Call Transcript - Insider Monkey

Click here to get full coverage on Theravance Biopharma to Participate in an Upcoming Investor Conference | TBPH Stock News - GuruFocus

Theravance Biopharma to Participate in an Upcoming Investor Conference | TBPH Stock News  GuruFocus

Theravance Biopharma to Participate in an Upcoming Investor Conference | TBPH Stock News - GuruFocus

Click here to get full coverage on Theravance Biopharma Announces Ampreloxetine Presentations at the International MSA Congress | TBPH Stock News - GuruFocus

Theravance Biopharma Announces Ampreloxetine Presentations at the International MSA Congress | TBPH Stock News  GuruFocus

Theravance Biopharma Announces Ampreloxetine Presentations at the International MSA Congress | TBPH Stock News - GuruFocus

Click here to get full coverage on Theravance's Q1 Loss Wider Than Expected, Revenues Rise Y/Y - TradingView

Theravance's Q1 Loss Wider Than Expected, Revenues Rise Y/Y  TradingView

Theravance's Q1 Loss Wider Than Expected, Revenues Rise Y/Y - TradingView

Click here to get full coverage on Earnings To Watch: Theravance Biopharma Inc (TBPH) Reports Q4 20 - GuruFocus

Earnings To Watch: Theravance Biopharma Inc (TBPH) Reports Q4 20  GuruFocus

Earnings To Watch: Theravance Biopharma Inc (TBPH) Reports Q4 20 - GuruFocus

Click here to get full coverage on Theravance Biopharma, Inc. Reports Third Quarter 2024 Financial Results and Announces Initiatives to Unlock Shareholder Value - PR Newswire

Theravance Biopharma, Inc. Reports Third Quarter 2024 Financial Results and Announces Initiatives to Unlock Shareholder Value  PR Newswire

Theravance Biopharma, Inc. Reports Third Quarter 2024 Financial Results and Announces Initiatives to Unlock Shareholder Value - PR Newswire

Click here to get full coverage on Theravance Biopharma: Clinical Progress Is Not Enough To Make It Attractive - Seeking Alpha

Theravance Biopharma: Clinical Progress Is Not Enough To Make It Attractive  Seeking Alpha

Theravance Biopharma: Clinical Progress Is Not Enough To Make It Attractive - Seeking Alpha

Click here to get full coverage on Theravance Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025 | TBPH Stock News - GuruFocus

Theravance Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025 | TBPH Stock News  GuruFocus

Theravance Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025 | TBPH Stock News - GuruFocus

Click here to get full coverage on Theravance Biopharma, Inc. (NASDAQ:TBPH) Q4 2024 Earnings Call Transcript - Insider Monkey

Theravance Biopharma, Inc. (NASDAQ:TBPH) Q4 2024 Earnings Call Transcript  Insider Monkey

Theravance Biopharma, Inc. (NASDAQ:TBPH) Q4 2024 Earnings Call Transcript - Insider Monkey

Click here to get full coverage on Theravance Biopharma Presents Two New Ampreloxetine Analyses in Oral Session at the American Academy of Neurology 2025 Annual Meeting - PR Newswire

Theravance Biopharma Presents Two New Ampreloxetine Analyses in Oral Session at the American Academy of Neurology 2025 Annual Meeting  PR Newswire

Theravance Biopharma Presents Two New Ampreloxetine Analyses in Oral Session at the American Academy of Neurology 2025 Annual Meeting - PR Newswire

Click here to get full coverage on Theravance Biopharma Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - simplywall.st

Theravance Biopharma Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags  simplywall.st

Theravance Biopharma Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - simplywall.st

Click here to get full coverage on Theravance Biopharma to Participate in an Upcoming Investor Conference - PR Newswire

Theravance Biopharma to Participate in an Upcoming Investor Conference  PR Newswire

Theravance Biopharma to Participate in an Upcoming Investor Conference - PR Newswire

Click here to get full coverage on Theravance Biopharma earnings missed by $0.05, revenue topped estimates - Investing.com

Theravance Biopharma earnings missed by $0.05, revenue topped estimates  Investing.com

Theravance Biopharma earnings missed by $0.05, revenue topped estimates - Investing.com

Click here to get full coverage on Theravance Biopharma Inc Surpasses Revenue Estimates with $58.3 Million in Q1 2025, Highlighting Strong Market Performance - GuruFocus

Theravance Biopharma Inc Surpasses Revenue Estimates with $58.3 Million in Q1 2025, Highlighting Strong Market Performance  GuruFocus

Theravance Biopharma Inc Surpasses Revenue Estimates with $58.3 Million in Q1 2025, Highlighting Strong Market Performance - GuruFocus

Click here to get full coverage on Theravance's Q4 Loss In Line With Estimates, Sales Beat - Yahoo

Theravance's Q4 Loss In Line With Estimates, Sales Beat  Yahoo

Theravance's Q4 Loss In Line With Estimates, Sales Beat - Yahoo

Click here to get full coverage on Theravance Biopharma, Inc. Announces Appointment of Jeremy Grant to Board of Directors - PR Newswire

Theravance Biopharma, Inc. Announces Appointment of Jeremy Grant to Board of Directors  PR Newswire

Theravance Biopharma, Inc. Announces Appointment of Jeremy Grant to Board of Directors - PR Newswire

Click here to get full coverage on Proposed simplified dissolution mechanism of cellulose in TBPH and after addition of protic and aprotic solvents - ResearchGate

Proposed simplified dissolution mechanism of cellulose in TBPH and after addition of protic and aprotic solvents  ResearchGate

Proposed simplified dissolution mechanism of cellulose in TBPH and after addition of protic and aprotic solvents - ResearchGate

Click here to get full coverage on Theravance Biopharma to Present New Ampreloxetine Data at the 2023 International Congress of Parkinson's Disease and Movement Disorders - PR Newswire

Theravance Biopharma to Present New Ampreloxetine Data at the 2023 International Congress of Parkinson's Disease and Movement Disorders  PR Newswire

Theravance Biopharma to Present New Ampreloxetine Data at the 2023 International Congress of Parkinson's Disease and Movement Disorders - PR Newswire

Click here to get full coverage on Theravance (TBPH) Suffers 2nd Study Failure in Two Months - Nasdaq

Theravance (TBPH) Suffers 2nd Study Failure in Two Months  Nasdaq

Theravance (TBPH) Suffers 2nd Study Failure in Two Months - Nasdaq

Click here to get full coverage on Theravance Biopharma Announces Results from the Phase 4 YUPELRI® PIFR-2 Study in Patients with Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD) - PR Newswire

Theravance Biopharma Announces Results from the Phase 4 YUPELRI® PIFR-2 Study in Patients with Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD)  PR Newswire

Theravance Biopharma Announces Results from the Phase 4 YUPELRI® PIFR-2 Study in Patients with Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD) - PR Newswire

Click here to get full coverage on Theravance Biopharma, Inc. Highlights 2022 Accomplishments and 2023 Key Targets - PR Newswire

Theravance Biopharma, Inc. Highlights 2022 Accomplishments and 2023 Key Targets  PR Newswire

Theravance Biopharma, Inc. Highlights 2022 Accomplishments and 2023 Key Targets - PR Newswire

Click here to get full coverage on Theravance Biopharma, Inc. Announces Orphan Drug Designation Granted to Ampreloxetine for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Patients with Multiple System Atrophy - PR Newswire

Theravance Biopharma, Inc. Announces Orphan Drug Designation Granted to Ampreloxetine for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Patients with Multiple System Atrophy  PR Newswire

Theravance Biopharma, Inc. Announces Orphan Drug Designation Granted to Ampreloxetine for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Patients with Multiple System Atrophy - PR Newswire

Click here to get full coverage on Theravance Biopharma, Inc. Announces Strategic Actions and Reports Fourth Quarter / Full Year 2022 Financial Results and Business Update - PR Newswire

Theravance Biopharma, Inc. Announces Strategic Actions and Reports Fourth Quarter / Full Year 2022 Financial Results and Business Update  PR Newswire

Theravance Biopharma, Inc. Announces Strategic Actions and Reports Fourth Quarter / Full Year 2022 Financial Results and Business Update - PR Newswire

Click here to get full coverage on Theravance Biopharma, Inc. Announces Enrollment of First Patient in YUPELRI® Phase 4 Study - PR Newswire

Theravance Biopharma, Inc. Announces Enrollment of First Patient in YUPELRI® Phase 4 Study  PR Newswire

Theravance Biopharma, Inc. Announces Enrollment of First Patient in YUPELRI® Phase 4 Study - PR Newswire

Click here to get full coverage on Thyroid disruption and oxidative stress in American kestrels following embryonic exposure to the alternative flame retardants, EHTBB and TBPH - ScienceDirect.com

Thyroid disruption and oxidative stress in American kestrels following embryonic exposure to the alternative flame retardants, EHTBB and TBPH  ScienceDirect.com

Thyroid disruption and oxidative stress in American kestrels following embryonic exposure to the alternative flame retardants, EHTBB and TBPH - ScienceDirect.com

Click here to get full coverage on Theravance Biopharma, Inc. Announces Results from Study 0170, a Second Phase 3 Study of Ampreloxetine, in Patients with Symptomatic Neurogenic Orthostatic Hypotension (nOH) - PR Newswire

Theravance Biopharma, Inc. Announces Results from Study 0170, a Second Phase 3 Study of Ampreloxetine, in Patients with Symptomatic Neurogenic Orthostatic Hypotension (nOH)  PR Newswire

Theravance Biopharma, Inc. Announces Results from Study 0170, a Second Phase 3 Study of Ampreloxetine, in Patients with Symptomatic Neurogenic Orthostatic Hypotension (nOH) - PR Newswire

Click here to get full coverage on Aggravated visual toxicity in zebrafish larvae upon co-exposure to titanium dioxide nanoparticles and bis(2-ethylhexyl)-2,3,4,5-tetrabromophthalate - ScienceDirect.com

Aggravated visual toxicity in zebrafish larvae upon co-exposure to titanium dioxide nanoparticles and bis(2-ethylhexyl)-2,3,4,5-tetrabromophthalate  ScienceDirect.com

Aggravated visual toxicity in zebrafish larvae upon co-exposure to titanium dioxide nanoparticles and bis(2-ethylhexyl)-2,3,4,5-tetrabromophthalate - ScienceDirect.com

Click here to get full coverage on Effects of novel brominated flame retardant TBPH and its metabolite TBMEHP on human vascular endothelial cells: Implication for human health risks - ScienceDirect.com

Effects of novel brominated flame retardant TBPH and its metabolite TBMEHP on human vascular endothelial cells: Implication for human health risks  ScienceDirect.com

Effects of novel brominated flame retardant TBPH and its metabolite TBMEHP on human vascular endothelial cells: Implication for human health risks - ScienceDirect.com

Click here to get full coverage on Theravance Biopharma, Inc. (NASDAQ:TBPH) Q3 2023 Earnings Call Transcript - Yahoo Finance

Theravance Biopharma, Inc. (NASDAQ:TBPH) Q3 2023 Earnings Call Transcript  Yahoo Finance

Theravance Biopharma, Inc. (NASDAQ:TBPH) Q3 2023 Earnings Call Transcript - Yahoo Finance

Click here to get full coverage on Seth Klarman's Strategic Reduction in Theravance Biopharma Inc - GuruFocus

Seth Klarman's Strategic Reduction in Theravance Biopharma Inc  GuruFocus

Seth Klarman's Strategic Reduction in Theravance Biopharma Inc - GuruFocus

Click here to get full coverage on Bis (2-ethylhexyl)-2,3,4,5-tetrabromophthalate showed poor penetrability but increased the permeability of blood brain barrier: Evidences from in vitro and in vivo studies - ScienceDirect.com

Bis (2-ethylhexyl)-2,3,4,5-tetrabromophthalate showed poor penetrability but increased the permeability of blood brain barrier: Evidences from in vitro and in vivo studies  ScienceDirect.com

Bis (2-ethylhexyl)-2,3,4,5-tetrabromophthalate showed poor penetrability but increased the permeability of blood brain barrier: Evidences from in vitro and in vivo studies - ScienceDirect.com

Click here to get full coverage on Characterization of the Fundulus heteroclitus embryo transcriptional response and development of a gene expression-based fingerprint of exposure for the alternative flame retardant, TBPH (bis (2-ethylhexyl)-tetrabromophthalate) - ScienceDirect.com

Characterization of the Fundulus heteroclitus embryo transcriptional response and development of a gene expression-based fingerprint of exposure for the alternative flame retardant, TBPH (bis (2-ethylhexyl)-tetrabromophthalate)  ScienceDirect.com

Characterization of the Fundulus heteroclitus embryo transcriptional response and development of a gene expression-based fingerprint of exposure for the alternative flame retardant, TBPH (bis (2-ethylhexyl)-tetrabromophthalate) - ScienceDirect.com

Click here to get full coverage on Eli Samaha buys $7.8 million worth of Theravance Biopharma stock By Investing.com - Investing.com Nigeria

Eli Samaha buys $7.8 million worth of Theravance Biopharma stock By Investing.com  Investing.com Nigeria

Eli Samaha buys $7.8 million worth of Theravance Biopharma stock By Investing.com - Investing.com Nigeria

Click here to get full coverage on Shareholders in Theravance Biopharma (NASDAQ:TBPH) are in the red if they invested five years ago - Yahoo

Shareholders in Theravance Biopharma (NASDAQ:TBPH) are in the red if they invested five years ago  Yahoo

Shareholders in Theravance Biopharma (NASDAQ:TBPH) are in the red if they invested five years ago - Yahoo

Click here to get full coverage on Irenic Sends Letter to Theravance Biopharma Regarding the Urgent Need for a Governance Overhaul, Capital Return and Strategic Review - Business Wire

Irenic Sends Letter to Theravance Biopharma Regarding the Urgent Need for a Governance Overhaul, Capital Return and Strategic Review  Business Wire

Irenic Sends Letter to Theravance Biopharma Regarding the Urgent Need for a Governance Overhaul, Capital Return and Strategic Review - Business Wire

Click here to get full coverage on Theravance Biopharma, Inc. Announces Top-line Results from a Phase 3 Study of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic Hypotension - PR Newswire

Theravance Biopharma, Inc. Announces Top-line Results from a Phase 3 Study of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic Hypotension  PR Newswire

Theravance Biopharma, Inc. Announces Top-line Results from a Phase 3 Study of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic Hypotension - PR Newswire

Click here to get full coverage on Here's Our Take On Theravance Biopharma Inc (NASDAQ:TBPH) and GlaxoSmithKline plc (ADR) (NYSE:GSK)'s Latest Submission - Yahoo Finance

Here's Our Take On Theravance Biopharma Inc (NASDAQ:TBPH) and GlaxoSmithKline plc (ADR) (NYSE:GSK)'s Latest Submission  Yahoo Finance

Here's Our Take On Theravance Biopharma Inc (NASDAQ:TBPH) and GlaxoSmithKline plc (ADR) (NYSE:GSK)'s Latest Submission - Yahoo Finance

Click here to get full coverage on A Helping Hand: RNA-Binding Proteins Guide Gene-Binding Choices by Cohesin Complexes - PLOS

A Helping Hand: RNA-Binding Proteins Guide Gene-Binding Choices by Cohesin Complexes  PLOS

A Helping Hand: RNA-Binding Proteins Guide Gene-Binding Choices by Cohesin Complexes - PLOS

Click here to get full coverage on Molecular structures of DEHP and TBPH and cleavage by hydrolysis or... - ResearchGate

Molecular structures of DEHP and TBPH and cleavage by hydrolysis or...  ResearchGate

Theravance Biopharma Inc (TBPH)

Price Chart

Key Statistics

Technicals

About TBPH

Latest News

Theravance Biopharma Inc (TBPH) Q1 2025 Earnings Call Highlights: Strong Sales Growth and ... - Yahoo Finance

Theravance Biopharma to Participate in an Upcoming Investor Conference - Stock Titan

Theravance Biopharma, Inc. Reports Record Fourth Quarter and Full Year 2024 Financial Results - PR Newswire

Advanced Charts

Top Gainers

Top Losers